文献速递膀胱癌与上尿路尿路上皮癌

免疫检查点抑制剂联合卡介苗治疗初治高危非肌层浸润性膀胱癌的疗效与安全性:ALBAN、CREST和POTOMAC试验的证据汇总

Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials.
PubMed 文献 · Eur Urol · 2025-12-31

该系统综述与meta分析纳入三项III期随机试验(POTOMAC、CREST、ALBAN;n=2590)的初治高危非肌层浸润性膀胱癌患者,比较BCG联合免疫检查点抑制剂与BCG单药。联合治疗与BCG维持组无事件生存期(EFS)优于单药(汇总HR 0.77,95%CI 0.60-0.99),但≥3级治疗相关不良事件更常见(RR 3.66-3.97),总生存无差异(HR 0.92)。

要点

  • BCG联合ICI改善无事件生存(HR 0.77,95%CI 0.60-0.99),证据确定性中等。
  • 联合治疗≥3级治疗相关不良事件风险显著增高(RR 3.66-3.97)。
  • 总生存无显著差异(HR 0.92,95%CI 0.67-1.26),需等待成熟生存数据。

核心结论

  • BCG联合ICI较BCG单药改善初治高危NMIBC的EFS,但增加高级别毒性,总生存无差异。
  • BCG单药仍是初治高危NMIBC的基准治疗,联合方案需谨慎个体化采用。

研究设计与样本

  • 系统综述与meta分析,纳入三项III期随机试验POTOMAC、CREST和ALBAN,共n=2590例初治高危NMIBC患者。
  • 所有研究总体偏倚风险低。

主要发现

  • 联合BCG维持治疗较BCG单药改善EFS(汇总HR 0.77,95%CI 0.60-0.99;Q=3.29,p=0.2)。
  • 基于ALBAN的高级别复发HR汇总估计方向一致但无统计学意义(HR 0.78,95%CI 0.58-1.04;Q=3.94,p=0.1)。
  • 总生存两组相当(HR 0.92,95%CI 0.67-1.26)。
  • ≥3级治疗相关不良事件联合治疗更常见(BCG诱导仅:RR 3.66,95%CI 2.56-5.24;BCG诱导+维持:RR 3.97,95%CI 2.54-6.21)。
  • ICI联合BCG维持组患者报告的生活质量中度下降。

关键数值与推荐

  • EFS的汇总HR为0.77(95%CI 0.60-0.99),证据确定性中等。
  • 高级别复发汇总HR为0.78(95%CI 0.58-1.04),无统计学意义。
  • 总生存HR为0.92(95%CI 0.67-1.26)。
  • ≥3级治疗相关不良事件RR:BCG诱导仅3.66(95%CI 2.56-5.24),BCG诱导+维持3.97(95%CI 2.54-6.21)。

临床怎么用

  • BCG单药仍为初治高危NMIBC的标准治疗。
  • 联合ICI可改善EFS但需权衡高级别毒性及生活质量下降,个体化决策。
  • 在成熟生存数据公布前,联合方案应谨慎采用。

局限性

  • 高级别复发汇总估计无统计学意义。
  • 总生存数据尚不成熟。
  • 生活质量在ICI联合BCG维持组出现中度下降。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intravesical bacillus Calmette-Guérin (BCG) therapy remains the cornerstone for high-risk non-muscle-invasive bladder cancer (NMIBC), but up to 40% of patients experience disease recurrence or progression within 2 yr. We conducted a systematic review and meta-analysis of three phase 3 randomized trials POTOMAC, CREST, and ALBAN; n = 2590) in BCG-naïve high-risk NMIBC disease treated with a combination of BCG and an immune checkpoint inhibitor (ICI). Overall risk of bias was low for all studies. Combination therapy with BCG maintenance was associated with better event-free survival (EFS) in comparison to BCG alone (pooled hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.60-0.99; Q = 3.29, p = 0.2). Using the HR for high-grade recurrence from ALBAN, the pooled estimate was directionally consistent, but not statistically significant (HR 0.78, 95% CI 0.58-1.04; Q = 3.94, p = 0.1). Overall survival was comparable between groups (HR 0.92, 95% CI 0.67-1.26). Grade ≥3 treatment-related adverse events were more frequent with combination therapy (risk ratio [RR] 3.66, 95% CI 2.56-5.24 for BCG induction only; RR 3.97, 95% CI 2.54-6.21 for BCG induction + maintenance). There was a moderate decline in patient-reported quality of life in the ICI + BCG maintenance arms. These findings are supported by moderate-certainty evidence for EFS. BCG monotherapy remains the benchmark for BCG-naïve high-risk NMIBC. ICI addition improves EFS but increases high-grade toxicity, which should prompt cautious and individualized adoption pending mature survival data.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Scilipoti P, Zaurito P, Longoni M, et al. Efficacy and Safety of Checkpoint Inhibitors Combined with Bacillus Calmette-Guérin (BCG) in BCG-naïve High-risk Non-muscle-invasive Bladder Cancer: Synthesis of Evidence from the ALBAN, CREST, and POTOMAC Trials. Eur Urol. 2025. PMID: 41478774. doi:10.1016/j.eururo.2025.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。